Correlation analysis of lymphocyte-monocyte ratio with pathological complete response and clinical prognosis of neoadjuvant chemotherapy in patients with breast cancer

被引:9
|
作者
Meng, Xiangyu [1 ]
Wang, Xueying [2 ]
Jiang, Cong [1 ]
Zhang, Shuai [3 ]
Cheng, Shaoqiang [1 ]
机构
[1] Harbin Med Univ Canc Hosp, Dept Breast Surg, Harbin 150081, Peoples R China
[2] Harbin Med Univ Canc Hosp, Dept Head & Neck Surg, Harbin 150081, Peoples R China
[3] Harbin Med Univ Canc Hosp, Dept Med Oncol 4, Harbin 150081, Peoples R China
来源
TRANSLATIONAL ONCOLOGY | 2022年 / 18卷
关键词
Lymphocyte-monocyte ratio (LMR); Breast cancer; Neoadjuvant chemotherapy; Pathological complete response; HER-2; INFLAMMATION; BIOMARKERS; PLATELET; NEUTROPHIL; SURVIVAL; PLR; NLR;
D O I
10.1016/j.tranon.2022.101355
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Inflammation plays an important role in tumor proliferation, metastasis, and chemotherapy resistance. Peripheral blood lymphocyte-monocyte ratio (LMR) has been reported to be closely associated with the prognosis of many tumors, such as certain hematologic malignancies and gastric cancer. However, the association in breast cancer is still not clear. This study investigated the relationship between LMR with pathological complete response and clinical prognosis of neoadjuvant chemotherapy in patients with breast cancer, to provide convenient and accurate predictive indicators for pathological complete response (pCR) and prognosis. Methods: The clinicopathological data of 192 female breast cancer patients who received neoadjuvant chemotherapy and surgery in Harbin Medical University Tumor Hospital from January 2013 to August 2017 were retrospectively analyzed. Blood lymphocytes and monocytes were obtained by peripheral venous punctures. Results: Compared with the low LMR group, pCR was more easily obtained in the high LMR group (P=0.020); Subgroup analysis showed that patients with the high LMR and HER-2(+) group were more likely to obtain pCR (P=0.011). Univariate andmultivariate results showed that the overall survival (OS) and disease free survival (DFS) of the high LMR group were longer than that of the low LMR group. Conclusion: LMR and HER-2 status are correlated with pCR of neoadjuvant chemotherapy in breast cancer patients and are independent predictors of pCR after neoadjuvant chemotherapy in breast cancer patients. Meanwhile, both LMR and T stage of tumor are independent prognostic factors of breast cancer patients, with good predictive value.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Pathological complete response and prognosis after neoadjuvant chemotherapy in patients with HER2-low breast cancer
    Qiao, Weiqiang
    Guo, Wanying
    Liu, Qipeng
    Guo, Xiao
    Deng, Miao
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2023, 64
  • [32] Association of tumor-infiltrating lymphocytes before and after neoadjuvant chemotherapy with pathological complete response and prognosis in patients with breast cancer
    Hong, Jin
    Rui, Weiwei
    Fei, Xiaochun
    Chen, Xiaosong
    Shen, Kunwei
    CANCER MEDICINE, 2021, 10 (22): : 7921 - 7933
  • [33] The Pretreatment Systemic Inflammation Response Index as a Useful Prognostic Factor is Better Than Lymphocyte to Monocyte Ratio in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
    Jiang, Cong
    Zhang, Shiyuan
    Qiao, Kun
    Xiu, Yuting
    Yu, Xiao
    Huang, Yuanxi
    CLINICAL BREAST CANCER, 2022, 22 (05) : 424 - 438
  • [34] Molecular Biomarkers Predict Pathological Complete Response of Neoadjuvant Chemotherapy in Breast Cancer Patients: Review
    Freitas, Ana Julia Aguiar de
    Causin, Rhafaela Lima
    Varuzza, Muriele Bertagna
    Hidalgo Filho, Cassio Murilo Trovo
    Silva, Vinicius Duval da
    Souza, Cristiano de Padua
    Marques, Marcia Maria Chiquitelli
    CANCERS, 2021, 13 (21)
  • [35] PROGNOSTIC SIGNIFICANT OF NEUTROPHIL: LYMPHOCYTE RATIO, PLATELET: LYMPHOCYTE RATIO, AND LYMPHOCYTE: MONOCYTE RATIO IN KURDISH PATIENTS WITH BREAST CANCER
    Khazaei, S.
    Tarlan, M.
    Madani, S. H.
    Jalilian, S.
    WORLD CANCER RESEARCH JOURNAL, 2022, 9
  • [36] Impact of pathological complete response to neoadjuvant chemotherapy in invasive breast cancer according to molecular subtype
    Cirier, J.
    Body, G.
    Jourdan, M. -L.
    Bedouet, L.
    Fleurier, C.
    Pilloy, J.
    Arbion, F.
    Ouldamer, L.
    GYNECOLOGIE OBSTETRIQUE FERTILITE & SENOLOGIE, 2017, 45 (10): : 535 - 544
  • [37] The Neutrophil to Lymphocyte Ratio has a High Negative Predictive Value for Pathologic Complete Response in Locally Advanced Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
    Eryilmaz, Melek Karakurt
    Mutlu, Hasan
    Salim, Derya Kivrak
    Musri, Fatma Yalcin
    Tural, Deniz
    Coskun, Hasan Senol
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (18) : 7737 - 7740
  • [38] Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy
    Garufi, Giovanna
    Carbognin, Luisa
    Sperduti, Isabella
    Miglietta, Federica
    Dieci, Maria Vittoria
    Mazzeo, Roberta
    Orlandi, Armando
    Gerratana, Lorenzo
    Palazzo, Antonella
    Fabi, Alessandra
    Paris, Ida
    Franco, Antonio
    Franceschini, Gianluca
    Fiorio, Elena
    Pilotto, Sara
    Guarneri, Valentina
    Puglisi, Fabio
    Conte, Pierfranco
    Milella, Michele
    Scambia, Giovanni
    Tortora, Giampaolo
    Bria, Emilio
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [39] Neutrophil-Lymphocyte Ratio and Pathological Response to Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
    Seah, Jo-An
    Leibowitz-Amit, Raya
    Atenafu, Eshetu G.
    Alimohamed, Nimira
    Knox, Jennifer J.
    Joshua, Anthony M.
    Sridhar, Srikala S.
    CLINICAL GENITOURINARY CANCER, 2015, 13 (04) : E229 - E233
  • [40] Prognostic implications of the peripheral platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in predicting pathologic complete response after neoadjuvant chemotherapy in breast cancer patients
    Jin, Xiaoyan
    Wang, Ke
    Shao, Xuan
    Huang, Jian
    GLAND SURGERY, 2022, 11 (06) : 1057 - 1066